Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance

Inovio Pharmaceuticals IncTrade
Live Nation Entertainment, Inc.Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Live Nation Entertainment, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Live Nation Entertainment, Inc. trades at $185.17 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is far larger — about 543.7× Inovio Pharmaceuticals Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOLYV
Market Cap
$78.55M$42.71B
Sector
HealthIndustrials
52-Week High
$2.87$186.59
52-Week Low
$0.66$125.61
Enterprise Value
$49.56M$44.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Live Nation Entertainment, Inc.

Live Nation (LYV) trades at $184.65, showing minimal daily movement (+0.01%) amid strong analyst support with 87% buy ratings. The stock maintains a bullish technical outlook with key resistance at $186 and support at $181. Recent Q2 2026 earnings beat expectations with $1.05 EPS versus $0.66 estimate, driven by record concert attendance and international demand growth. Revenue reached $25.2B in 2025, though net margins remain thin at 0.51%.

The outlook remains positive given robust demand for live events and raised 2026 guidance, but high valuation multiples (P/E 117.5) and legal/regulatory risks warrant caution. Insider selling activity and negative ROE (-116.7%) highlight execution challenges despite strong top-line performance. Upside to consensus $209.54 target depends on margin expansion and debt management.

Returns comparison

Trailing returns across standard periods

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Live Nation Entertainment, Inc.

Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.

Read more on LYV